Instructions for Credit — There is no fee for this activity. To receive credit for this CE activity, participants must review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.25 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers at the intermediate and advanced levels involved in the care of patients with chronic myeloid leukemia (CML).
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the symptoms and treatment of Chronic Myeloid Leukemia (CML)|
|•||Identify tests used to diagnose disease and monitor treatment of CML|
|•||Explain the overarching goals of treatment for the types of CML|
|•||Explain approved and emerging treatment options for CML, including stem cell transplantation, and the role of clinical trials|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for CML|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioners Credit Designation
This activity is approved for 1.25 contact hours of continuing education (which includes 1.25 hours pharmacology) by the American Association of Nurse Practitioners. Activity ID #19023595. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Social Work Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.25 CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.25 CE clinical contact hours for this activity.
For questions, grievances, or assistance with special needs (physical,. dietary, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest
All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Jorge Cortes, MD, is a Consultant and Clinical Investigator for: Bristol-Myers Squibb, Novartis, Pfizer, and Takeda Pharmaceutical Company.
Elizabeth S. Kaled, RN-BS, MS, NP-C, FNP-BC, has nothing to disclose.
Debbie McCue, PharmD, BCOP, is on the Advisory Board for Stemline Therapeutics, Inc.
Gail Sperling, MPH, CHES, has nothing to disclose.
Content Expert Reviewer Disclosure
Edythe M. Lyn Greenberg, PhD, RN, FNP-BC, Content Expert Reviewer, has nothing to disclose.
Disclaimer — The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: 1.25 hours|
|Date of initial release: April 1, 2019|
|Valid for CME credit through April 1, 2020|
Jorge Cortes, MD, is Chief of the CML and AML Sections in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.He is also Deputy Chair and Professor of Medicine in the Department of Leukemia. He led the development of 3 drugs that were approved by the US Food and Drug Administration for the treatment of chronic myeloid leukemia in 2012.
Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, Mexico City, and has been at MD Anderson Cancer Center since 1991. Dr. Cortes, whose clinical interests focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders, has authored more than 900 peer-reviewed medical publications in top-tier journals, including the New England Journal of Medicine, Lancet Oncology, Lancet Hematology, the Journal of Clinical Oncology, Leukemia, Blood, and many others. Dr. Cortes is an Associate Editor for Blood and serves on the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia & Lymphoma, and the American Journal of Hematology. He has authored several books and book chapters in prestigious publications such as Cancer Medicine and Harrison’s Principles of Internal Medicine.
He has received numerous awards including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, the Dr. John J. Kenny Award from the Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from the Leukemia & Lymphoma Society in 2007, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007, the Professor David Galton Lecture from the Imperial College of London Hammersmith Hospital in London, UK, in 2011, the William Randolph Hearst Foundations Faculty Achievement Award in Education in 2013, and the Gerald P. Bodey Award for Excellence in Education in 2014.
He was listed in “A list of highly influential biomedical researchers, 1996-2011,” (Boyack et al. Eur J Clin Invest. 2013;43:1339-1365), and named among the Highly Cited Researchers in 2014 by Thomson Reuters.
Dr. Cortes is a member of the Board of Directors of the International Chronic Myeloid Leukemia Foundation and President of the Latin American Leukemia Net. Dr. Cortes is Chair of the Executive Institutional Review Board, Executive Director of the MD Anderson Cancer Center for the Division of Cancer Medicine, and Program Director of the Leukemia Fellowship Program.
Elizabeth S. Kaled, RN-BS, MS, NP-C, FNP-BC, is an Advanced Practice Nurse in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. In her current position, Ms. Kaled works with adult leukemia patients in the inpatient and outpatient settings, where she provides total care by addressing comorbid conditions and side effects of cancer medications.
Ms. Kaled has worked with cancer patients for over 40 years as a nurse, head nurse, and advanced practice nurse. She began her career at Rosewell Park Institute in Buffalo, New York, working with patients with genitourinary cancers, and has worked with adult leukemia patients at The MD Anderson Cancer Center since 1978.
Deborah McCue, PharmD, BCOP, is Manager of Clinical Pharmacy Services within the Division of Pharmacy an at The University of Texas MD Anderson Cancer Center in Houston, Texas. She is also an Oncology Clinical Pharmacy Specialist. Dr. McCue received her Doctor of Pharmacy degree from the University of Maryland School of Pharmacy in Baltimore, Maryland, and completed her pharmacy Practice Residency at the Veterans Affairs Medical Center in the Bronx, New York. She completed her Oncology Pharmacy Practice Residency at the MD Anderson Cancer Center. She has been a Board Certified Oncology Pharmacist since 1999. Her current area of practice and research is adult patients with hematologic malignancies.
Gail Sperling, MPH, CHES, has been with The Leukemia & Lymphoma Society (LLS) for 18 years, as a Patient Services Manager and Community Outreach Manager in the Los Angeles and Orange County/Inland Empire Chapters for 13 years and as an Information Specialist in the Information Resource Center (IRC) for the past five years.
In her roles as Patient Services Manager and Community Outreach Manager, Ms. Sperling led efforts to provide outreach to the community and health care professionals and coordinate a variety of disease- and patient-focused programs including Family Support Groups, Patient Financial Aid, Back-to-School Initiative, First Connection Peer Support, Chapter Advocacy efforts, Patient and Professional Education. She worked closely with cancer centers, medical groups and community oncology practices to increase referral and utilization of LLS programs and services.
Additionally, Ms. Sperling served on two committees for California Dialogue on Cancer, the organization responsible for the development of the California Comprehensive Cancer Plan and on the strategic planning committee for the Orange County Cancer Coalition and the Inland Empire Access to Cancer Care Coalition.
In her current role as Senior Manager of the IRC, Ms. Sperling provides resources and referrals to assure that all callers to the IRC have access to information, treatment, and support services that meet the callers’ unique needs at diagnosis, relapse, or any time during the cancer journey.
As an Information Specialist, Ms. Sperling helps patients and their families navigate through treatment, financial, and social challenges and provides accurate, up-to-date disease and treatment information. As Senior Manager, she supervises and supports Information Specialists working remotely in different areas. She also serves as an LLS liaison in various pharma-related capacities and currently serves as the North American representative to the CML Advocates, an international chronic myeloid leukemia (CML) organization.
Ms. Sperling draws her inspiration and passion for her work with the LLS from her mother, Bernice, and friend, Diane, both of whom she lost to a blood cancer. Every day she feels privileged to be a part of the Patient Access Team and work with blood cancer patients, families, and health care providers.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
CML Specific Resources – www.LLS.org/CML
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Additional support resources: www.LLS.org/support
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.